UnitedHealth falls 1.3% as investors focus on upcoming third-quarter report

What happened

UnitedHealth (UNH) fell 1.3% on October 8, 2026, as investors weighed preview items and modest intraday weakness ahead of its third-quarter report due October 13, according to Zacks Investment Research. The stock closed at $370.95 after opening 0.2% below the previous close, with trading volume 1.5 times its 20-day average. Market breadth was weak: the S&P 500 fell 0.5% and the healthcare sector median fell 0.5% on the day, leaving the stock 0.8 percentage points worse than its sector median.

How big was the move

The day’s decline amounted to 1.0 times a typical daily move for this stock, a size that market data classify as an ordinary session. Over the last five sessions the stock rose 1.6% while the S&P 500 rose 1.3% in the same period. The stock’s market sensitivity is modest, with a beta of 0.44, indicating it tends to move less than the market. Volume was elevated relative to recent trading, but the session did not qualify as an unusually large or rare move for UnitedHealth.

The technical picture

Technically, the stock sat 1.1% below its 20-day moving average and 4.9% below its 50-day moving average, while remaining 3.8% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock has spent 125 consecutive trading days above the 200-day average. Momentum indicators were neutral: the Relative Strength Index (14 days) was 41, in the 30-to-70 range. The stock traded 19.6% below its 52-week high and showed pressure in recent months, falling 5.6% over one month and 12.6% over three months, though it rose 2.0% over one year, 13.6 percentage points behind the S&P 500. Volatility was modest, at 21% annualized over 60 days, lower than 82% of its own readings over five years.

Fundamentals and valuation

On fundamentals, revenue for the four quarters through June 30, 2026, totaled $450.13 billion, up 6.5% from a year earlier. Diluted earnings per share for that period were $15.55, down 32.6% from a year earlier. Gross margin expanded to 22.5% from 20.8% a year earlier, while operating margin narrowed to 4.8% from 7.3%. Free-cash-flow margin stood at 5.2% and return on invested capital was 9.2%. The balance sheet shows net debt of 1.7 times EBITDA, and share count decreased by 0.4% over one year.

Valuation metrics show the stock trading at 23.9 times trailing earnings and 18.6 times expected forward earnings, with a free-cash-flow yield of 7.0%. Its price-to-earnings ratio is lower than 57% of its own readings over the past five years; the five-year median is 26.4 times earnings. PromtFinance scores rank the company highly on Value at 91 (Exceptional) and Stability at 85 (Strong), while Growth scores 29 (Very weak) and Quality scores 70 (Positive). Analysts set a consensus price target of $473.89, 27.8% above the closing price.

Earnings and analyst expectations

UnitedHealth is scheduled to report third-quarter 2026 results on October 13, 2026, before the opening bell, with the Zacks Consensus Estimate at $4.12 per share and revenues of $111.38 billion, according to Zacks Investment Research. In its last report, on July 16, 2026, the company reported earnings per share of $6.38 against $4.94 expected, 29.1% above estimates. That marked a fourth consecutive quarter beating estimates, with an average surprise of 11.5% above estimates over the last four reports. Typical two-day market reactions after recent reports have seen the stock fall 6.9%.

What to watch

• October 13, 2026: UnitedHealth scheduled to report third-quarter 2026 results before the opening bell (Zacks Consensus Estimate: $4.12 per share; revenues: $111.38 billion).
• July 16, 2026: Last report showed earnings per share of $6.38 against $4.94 expected, 29.1% above estimates; four consecutive quarters beating estimates.
• Trading volume on October 8, 2026: 1.5 times its 20-day average.
• Valuation: 23.9 times trailing earnings and consensus price target $473.89, 27.8% above the closing price.
• Balance sheet and cash flow: net debt of 1.7 times EBITDA and free-cash-flow yield of 7.0%.